---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003937"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:27:38.927934+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics outlines 2024 priorities: WTX-124/330 data, cash runway through Q1 2025

## Summary
- WTX-124: updated monotherapy and initial combo data expected in 1H 2024; RDE selection and dose expansion planned.
- WTX-330: preliminary Phase 1 monotherapy data expected in Q2 2024.
- Preclinical candidates WTX-712 (IL-21) and WTX-518 (IL-18) advancing; preclinical data in 1H 2024.
- Cash guidance extended: resources sufficient through at least Q1 2025.
- Company seeking partners for non-oncology applications of INDUKINE platform, e.g., inflammatory diseases.

## SEC filing metadata
- accession: 0001193125-24-003937
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000119312524003937/0001193125-24-003937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000119312524003937/d873870d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003937
- JSON: https://secwatch.observer/filing/0001193125-24-003937.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003937.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.